Researchers at Oregon State University have developed an iron-based nanomaterial that destroys cancer cells by triggering two simultaneous chemical reactions inside tumors, causing complete tumor elimination in mouse models without damaging healthy tissue or producing side effects.
The work, led by Oleh Taratula, Olena Taratula, and Chao Wang from the OSU College of Pharmacy, was published in Advanced Functional Materials. It builds on chemodynamic therapy, a treatment strategy that exploits the distinct chemical environment found inside tumors.
How the Material Works
Cancer cells differ from healthy tissue in two key ways: they are more acidic and carry higher concentrations of hydrogen peroxide. Chemodynamic therapy uses these conditions to trigger the formation of hydroxyl radicals, reactive oxygen molecules that damage cancer cells by stripping electrons from lipids, proteins, and DNA.
Most existing agents generate either hydroxyl radicals or singlet oxygen, a second type of reactive oxygen species. Not both. The OSU team built a nanoagent from an iron-based metal-organic framework capable of producing both simultaneously, effectively doubling the oxidative assault on tumor cells.
“Existing CDT agents are limited,” Oleh Taratula said. “They efficiently generate either radical hydroxyls or singlet oxygen but not both, and they often lack sufficient catalytic activity to sustain robust reactive oxygen species production. Consequently, preclinical studies often only show partial tumor regression and not a durable therapeutic benefit.”
Results in Mice
In laboratory testing, the material showed strong toxicity across multiple cancer cell lines while causing minimal harm to noncancerous cells. The real test came in live animal models bearing human breast cancer cells.
“When we systemically administered our nanoagent in mice bearing human breast cancer cells, it efficiently accumulated in tumors, robustly generated reactive oxygen species and completely eradicated the cancer without adverse effects,” Olena Taratula said. “We saw total tumor regression and long-term prevention of recurrence, all without seeing any systemic toxicity.”
Tumors disappeared entirely and did not return. The animals showed no detectable signs of harm from the treatment.
What Comes Next
Before any human trials, the team plans to test the nanoagent against additional cancer types. Aggressive pancreatic cancer is specifically identified as a priority, given how resistant it tends to be to existing therapies.
Additional contributors to the study from Oregon State included Kongbrailatpam Shitaljit Sharma, Yoon Tae Goo, Vladislav Grigoriev, Constanze Raitmayr, Ana Paula Mesquita Souza, and Manali Parag Phawde. Funding came from the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both part of the National Institutes of Health.
The results are preclinical, and the distance from mouse models to approved human therapies is long. Still, complete tumor regression with zero systemic toxicity in animal trials is a result that moves this approach worth watching into serious scientific territory.
Photo by Terence Tham on Unsplash
This article is a curated summary based on third-party sources. Source: Read the original article
